PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.\', \'Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.\', \'Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.\', \'Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, USA.\', \'Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.\', \'Department of Pathology, and Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.\', \'Vir Biotechnology, St. Louis, MO, USA.\', \'Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.\', \'The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.\', \'Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.\', \'Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.\', \'Department of Biochemistry & Molecular Biophysics, Washington University School of Medicine, St. Louis, MO, USA.\', \'Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. mdiamond@wustl.edu.\', \'Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA. mdiamond@wustl.edu.\', \'Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA. mdiamond@wustl.edu.\', \'Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO, USA. mdiamond@wustl.edu.\', \'Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St. Louis, MO, USA. mdiamond@wustl.edu.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41591-021-01678-y
?:hasPublicationType
?:journal
  • Nature medicine
is ?:pmid of
?:pmid
?:pmid
  • 35046573
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 17.067
?:rankingScore_hIndex
  • 484
is ?:relation_isRelatedTo_publication of
?:title
  • An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all